Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial

ConclusionIn CS patients, cDPP3 gives an early prediction of outcome, including development of refractory status and/or survival.Clinical Trial Registration:clinicaltrials.gov Identifier NCT01367743

Source: European Journal of Heart Failure - August 30, 2019 Category: Cardiology Authors: Koji Takagi, Alice Blet, Bruno Levy, Benjamin Deniau, Feriel Azibani, Elodie Feliot, Andreas Bergmann, Karine Santos, Oliver Hartmann, Etienne Gayat, Alexandre Mebazaa, Antoine Kimmoun Tags: Research Article Source Type: research